PulseAugur
EN
LIVE 21:16:12
中文(ZH) 东诚药业：注射用甲磺酸萘莫司他上市许可申请获受理

Dongcheng Pharma seeks approval for injectable nafamostat mesylate

By PulseAugur Editorial · [1 sources] ·

Dongcheng Pharmaceutical's subsidiary, Yantai Dongcheng Northern Pharmaceutical, has received acceptance for its marketing authorization application for injectable nafamostat mesylate. This drug already has similar products available internationally and one domestic first-copy generic on the market. Sales data indicates that injectable nafamostat mesylate generated 442 million yuan in sales in hospitals above Grade II during the first three quarters of 2025. AI

RANK_REASON The cluster reports on a regulatory filing for a pharmaceutical product, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Dongcheng Pharma seeks approval for injectable nafamostat mesylate

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The cluster reports on a regulatory filing for a pharmaceutical product, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, paper
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
111 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Dongcheng Pharmaceutical: Application for Marketing Authorization of Mosatamide Mesylate for Injection Accepted

    东诚药业6月7日公告，近日，全资子公司烟台东诚北方制药有限公司收到国家药品监督管理局核准签发的关于注射用甲磺酸萘莫司他上市许可申请的《受理通知书》。目前国内仅有1家首仿上市，国外已有同类产品上市，根据魔熵医药销售数据查询系统得知，注射用甲磺酸萘莫司他2025年前三个季度二级以上医院销售额为4.42亿元。

RELATED TOPICS